Edition:
India

Ablynx NV (ABLX.OQ)

ABLX.OQ on NASDAQ Stock Exchange Global Select Market

54.62USD
1:30am IST
Change (% chg)

$-0.29 (-0.53%)
Prev Close
$54.91
Open
$54.84
Day's High
$54.84
Day's Low
$54.46
Volume
15,906
Avg. Vol
53,795
52-wk High
$55.27
52-wk Low
$17.75

Select another date:

Thu, Apr 5 2018

Novo Nordisk buys blood drug licence to boost anaemic biopharma business

COPENHAGEN Danish drugmaker Novo Nordisk has secured the global licence for U.S. biotech company EpiDestiny's sickle cell disease (SCD) program in a bid to offset declining sales in its biopharmaceutical business.

BRIEF-Ablynx Says Tender Offers By Sanofi To Acquire Co To Commence On April 4

* PREVIOUSLY ANNOUNCED TENDER OFFERS BY SANOFI TO ACQUIRE ABLYNX WILL COMMENCE ON APRIL 4, 2018

BRIEF-Ablynx ‍Announces Topline Results From Phase II Study Of Vobarilizumab

* ‍ANNOUNCES TOPLINE RESULTS FROM PHASE II STUDY OF VOBARILIZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS​

BRIEF-Ablynx NV ‍Ablynx Commences Dosing In Its Phase II Study Of Alx-0171 In Hospitalised Japanese Infants With A Rsv Infection​

* ‍ABLYNX COMMENCES DOSING IN ITS PHASE II STUDY OF ALX-0171 IN HOSPITALISED JAPANESE INFANTS WITH A RSV INFECTION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Reg-Sanofi Announces Receipt Of Antitrust Clearances In Connection With The Acquisition Of Ablynx

* Sanofi has received clearance from the Federal Cartel Office of Germany in accordance with the Act Against Restraints of Competition, applicable to Sanofi's proposed acquisition of Ablynx NV

BRIEF-Ablynx FY Operating Loss Widens To 54.2‍​ Million Euros

* FY OPERATING LOSS OF EUR 54.2‍​ MILLION VERSUS LOSS OF EUR 28.6 MILLION YEAR AGO

BRIEF-Ablynx Announces Option Exercise By Sanofi To License Two Additional Target Combinations​

* ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

PARIS/LONDON French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ. | Video

Sanofi beats Novo to buy Ablynx for $4.8 billion in biotech M&A boom

PARIS/LONDON French drugmaker Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), beating Novo Nordisk and marking its second big deal this month after buying Bioverativ. | Video

LIVE MARKETS-Closing snapshot: STOXX 600 edges lower

* European shares dip * Heavy earnings week begins * AMS soars after raising outlook, doubling revenue * Sanofi buys Ablynx for 3.9 bln euros, Ablynx +20% Jan 29 Welcome to the home for real time coverage of European equity markets brought to you by Reuters stocks reporters and anchored today by Helen Reid. Reach her on Messenger to share your thoughts on market moves: helen.reid.thomsonreuters.com@reuters.net CLOSING SNAPSHOT: STOXX 600 EDGES LOWER (163

Select another date: